


PHARMACEUTICAL 2022

Cyteir Therapeutics Inc. Rank 117 of 475







RealRate

Cyteir Therapeutics Inc. Rank 117 of 475

The relative strengths and weaknesses of Cyteir Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyteir Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 237% points. The greatest weakness of Cyteir Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 311% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	193,077
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,511
Liabilities, Non-Current	201
Other Assets	256
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	384
Other Net Income	133
Property and Equipment	2,055
Research and Development	30,959
Revenues	0
Selling, General and Administrative Expense	11,300

Output Variable	Value in 1000 USD
Assets	195,388
Liabilities	8,096
Expenses	42,259
Stockholders Equity	187,292
Net Income	-42,126
Comprehensive Net Income	-42,126
Economic Capital Ratio	34%

